These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 16254024)

  • 1. Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients.
    Del Mastro L; Catzeddu T; Boni L; Bell C; Sertoli MR; Bighin C; Clavarezza M; Testa D; Venturini M
    Ann Oncol; 2006 Jan; 17(1):74-8. PubMed ID: 16254024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial.
    Del Mastro L; Boni L; Michelotti A; Gamucci T; Olmeo N; Gori S; Giordano M; Garrone O; Pronzato P; Bighin C; Levaggi A; Giraudi S; Cresti N; Magnolfi E; Scotto T; Vecchio C; Venturini M
    JAMA; 2011 Jul; 306(3):269-76. PubMed ID: 21771987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of leuprolide acetate on ovarian function after cyclophosphamide-doxorubicin-based chemotherapy in premenopausal patients with breast cancer: results from a phase II randomized trial.
    Song G; Gao H; Yuan Z
    Med Oncol; 2013; 30(3):667. PubMed ID: 23904400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer.
    Munster PN; Moore AP; Ismail-Khan R; Cox CE; Lacevic M; Gross-King M; Xu P; Carter WB; Minton SE
    J Clin Oncol; 2012 Feb; 30(5):533-8. PubMed ID: 22231041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC).
    Urruticoechea A; Arnedos M; Walsh G; Dowsett M; Smith IE
    Breast Cancer Res Treat; 2008 Aug; 110(3):411-6. PubMed ID: 17851753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study.
    Gerber B; von Minckwitz G; Stehle H; Reimer T; Felberbaum R; Maass N; Fischer D; Sommer HL; Conrad B; Ortmann O; Fehm T; Rezai M; Mehta K; Loibl S;
    J Clin Oncol; 2011 Jun; 29(17):2334-41. PubMed ID: 21537042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Goserelin as ovarian protection in the adjuvant treatment of premenopausal breast cancer: a phase II pilot study.
    Recchia F; Sica G; De Filippis S; Saggio G; Rosselli M; Rea S
    Anticancer Drugs; 2002 Apr; 13(4):417-24. PubMed ID: 11984088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women.
    Robertson JF; Blamey RW
    Eur J Cancer; 2003 May; 39(7):861-9. PubMed ID: 12706354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of goserelin in the treatment of breast cancer.
    Rody A; Loibl S; von Minckwitz G; Kaufmann M
    Expert Rev Anticancer Ther; 2005 Aug; 5(4):591-604. PubMed ID: 16111461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Luteinizing hormone-releasing hormone analogues--the rationale for adjuvant use in premenopausal women with early breast cancer.
    Jonat W
    Br J Cancer; 1998 Sep; 78 Suppl 4(Suppl 4):5-8. PubMed ID: 9741781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.
    ; Castiglione-Gertsch M; O'Neill A; Price KN; Goldhirsch A; Coates AS; Colleoni M; Nasi ML; Bonetti M; Gelber RD
    J Natl Cancer Inst; 2003 Dec; 95(24):1833-46. PubMed ID: 14679153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of ovarian function after chemotherapy in women with early and locally advanced breast cancer from Serbia.
    Malisic E; Susnjar S; Milovanovic J; Todorovic-Rakovic N; Kesic V
    Arch Gynecol Obstet; 2018 Feb; 297(2):495-503. PubMed ID: 29101609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII.
    Bernhard J; Zahrieh D; Castiglione-Gertsch M; Hürny C; Gelber RD; Forbes JF; Murray E; Collins J; Aebi S; Thürlimann B; Price KN; Goldhirsch A; Coates AS;
    J Clin Oncol; 2007 Jan; 25(3):263-70. PubMed ID: 17159194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical Trial.
    Lambertini M; Boni L; Michelotti A; Gamucci T; Scotto T; Gori S; Giordano M; Garrone O; Levaggi A; Poggio F; Giraudi S; Bighin C; Vecchio C; Sertoli MR; Pronzato P; Del Mastro L;
    JAMA; 2015 Dec 22-29; 314(24):2632-40. PubMed ID: 26720025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.
    Moore HC; Unger JM; Phillips KA; Boyle F; Hitre E; Porter D; Francis PA; Goldstein LJ; Gomez HL; Vallejos CS; Partridge AH; Dakhil SR; Garcia AA; Gralow J; Lombard JM; Forbes JF; Martino S; Barlow WE; Fabian CJ; Minasian L; Meyskens FL; Gelber RD; Hortobagyi GN; Albain KS;
    N Engl J Med; 2015 Mar; 372(10):923-32. PubMed ID: 25738668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF).
    Fogelman I; Blake GM; Blamey R; Palmer M; Sauerbrei W; Schumacher M; Serin D; Stewart A; Wilpshaar W
    Osteoporos Int; 2003 Dec; 14(12):1001-6. PubMed ID: 14530912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian suppression/ablation in premenopausal ER-positive breast cancer patients. Issues and recommendations.
    Pritchard KI
    Oncology (Williston Park); 2009 Jan; 23(1):27-33. PubMed ID: 19283918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study.
    Badawy A; Elnashar A; El-Ashry M; Shahat M
    Fertil Steril; 2009 Mar; 91(3):694-7. PubMed ID: 18675959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Goserelin (Zoladex)--its role in early breast cancer in pre- and perimenopausal women.
    Jonat W
    Br J Cancer; 2001 Nov; 85 Suppl 2(Suppl 2):1-5. PubMed ID: 11900209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study.
    Jonat W; Kaufmann M; Sauerbrei W; Blamey R; Cuzick J; Namer M; Fogelman I; de Haes JC; de Matteis A; Stewart A; Eiermann W; Szakolczai I; Palmer M; Schumacher M; Geberth M; Lisboa B;
    J Clin Oncol; 2002 Dec; 20(24):4628-35. PubMed ID: 12488406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.